Aratana Therapeutics to Present GALLIPRANT® (grapiprant tablets) Pivotal Data
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Wall Street sinks as bond yields rise, Walmart results disappoint
Jefferies Reiterates Buy on Aratana Therapeutics (PETX) Following US Galliprant Approval
April 1, 2016 8:25 AM EDTJefferies reiterated a Buy rating and $12.00 price target on Aratana Therapeutics (NASDAQ: PETX) following the company's US approval of Galliprant (AT-001). Galliprant is expected to be available to US veterinarians in Q3'16. Jefferies sees this as a lucrative opportunity, given 9.7m dogs... More
